top of page


The broadly protective malaria vaccine combination


The CAPTIVATE project, supported by the European Union’s Horizon Europe research and innovation programme, brings together experts from Europe and Australia in an integrated interdisciplinary approach aimed at developing the next generation of malaria vaccines to the clinic.

The Consortium will be supported by an independent Scientific and Ethics Advisory Committee (SEAC) to facilitate the achievement of the established objectives, playing a crucial role in providing strategic input on scientific, technical, and ethical issues.

Science Student

OUR MISSIONis to createa next-generationmalaria vaccinethat targets multiplestages of the deadliestmalaria parasite,P. falciparum.

At a glance


1 November 2023

to 30 April 2028


European Comission


European Vaccine Initiative (EVI)


€8.2 Million

Abstract Background

Plasmodium falciparum, the deadliest malaria parasite, remains a severe global health threat. In 2022, 249 million cases and 608,000 fatalities were reported, with children under 5 constituting 78,1% of malaria-related deaths in the WHO African Region. Despite years of dedicated efforts within the scientific community to develop malaria vaccines, there are still important challenges to tackle.


To pursue our mission, an innovative vaccine development program will be set up consisting of combination vaccine approaches covering multiple parasite life cycle stages, traditional immunological analyses, innovative single immune cell sequencing, and artificial intelligence (AI) to assist in the understanding of the mechanisms of adaptive protective immunity.


From generating new scientific knowledge on malaria field to developing a more effective vaccine, the CAPTIVATE project holds the potential to significantly impact various aspects of scientific, economic, technological, medical, and societal domains.

bottom of page